Weighted blood marker better predicted heart and stroke risk
Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.Absolute reductions in the risk of heart and stroke events with alirocumab versus placebo ranged from 0.5 to 4 percentage points across the marker’s range.